Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;24(1):33-39.
doi: 10.3747/co.24.3470. Epub 2017 Feb 27.

A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma

D MacDonald  1 , T Crosbie  2 , A Christofides  3 , W Assaily  4 , J Wiernikowski  5
Affiliations
Review

A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma

D MacDonald et al. Curr Oncol. 2017 Feb.

Abstract

Rituximab is widely used for the treatment of non-Hodgkin lymphoma, being a key component in most therapeutic regimens. Administration of the intravenous (IV) formulation is lengthy and places a significant burden on health care resources and patient quality of life. A subcutaneous (sc) formulation that provides a fixed dose of rituximab is being examined in a number of studies. Results indicate that the pharmacokinetics are noninferior and response rates are comparable to those obtained with the IV formulation. Moreover, the sc formulation is preferred by patients and health care providers and reduces administration and chair time. Additional advantages include a lesser potential for dosing errors, shorter preparation time, reduced drug wastage, and fewer infusion-related reactions. Despite the success of the sc formulation, correct administration is needed to reduce administration-related reactions. By using a careful procedure, the sc formulation can be given safely and effectively, potentially reducing the burden on health care resources and improving quality of life for patients.

Keywords: Rituximab (subcutaneous); lymphoma; non-Hodgkin lymphoma.

PubMed Disclaimer

References

    1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics: 2016. Toronto, ON: Canadian Cancer Society; 2016.
    1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:717–20. doi: 10.1023/A:1008265532487. - DOI - PubMed
    1. Kuruvilla J, Assouline S, Hodgson D, et al. A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board. Clin Lymphoma Myeloma Leuk. 2015;15:59–74. doi: 10.1016/j.clml.2014.07.015. - DOI - PubMed
    1. Hoffmann–La Roche Ltd. Rituxan SC: Rituximab 120 mg/mL Solution for Subcutaneous Injection [product monograph]. Mississauga, ON: Hoffmann–La Roche; 2014.
    1. Carlson J, Cox K, Bedwell K, Ku M. Rituximab for subcutaneous delivery: clinical management principles from a nursing perspective. Int J Nurs Pract. 2015;21(suppl 3):1–13. doi: 10.1111/ijn.12413. - DOI - PubMed

LinkOut - more resources